8 research outputs found

    Data driven discovery of cyber physical systems

    Get PDF
    Cyber-physical systems embed software into the physical world. They appear in a wide range of applications such as smart grids, robotics, and intelligent manufacturing. Cyber-physical systems have proved resistant to modeling due to their intrinsic complexity arising from the combination of physical and cyber components and the interaction between them. This study proposes a general framework for discovering cyber-physical systems directly from data. The framework involves the identification of physical systems as well as the inference of transition logics. It has been applied successfully to a number of real-world examples. The novel framework seeks to understand the underlying mechanism of cyber-physical systems as well as make predictions concerning their state trajectories based on the discovered models. Such information has been proven essential for the assessment of the performance of cyber- physical systems; it can potentially help debug in the implementation procedure and guide the redesign to achieve the required performance

    Dynamical network size estimation from local observations

    Get PDF
    Here we present a method to estimate the total number of nodes of a network using locally observed response dynamics. The algorithm has the following advantages: (a) it is data-driven. Therefore it does not require any prior knowledge about the model; (b) it does not need to collect measurements from multiple stimulus; and (c) it is distributed as it uses local information only, without any prior information about the global network. Even if only a single node is measured, the exact network size can be correctly estimated using a single trajectory. The proposed algorithm has been applied to both linear and nonlinear networks in simulation, illustrating the applicability to real-world physical networks. © 2020 The Author(s). Published by IOP Publishing Ltd on behalf of the Institute of Physics and Deutsche Physikalische Gesellschaft

    Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

    No full text
    ABSTRACTPulmonary arterial hypertension (PAH) is a disease with a high mortality and few treatment options to prevent the development of pulmonary vessel remodeling, pulmonary vascular resistance, and right ventricular failure. Canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is originally used in diabetes patients which could assist the glucose excretion and decrease blood glucose. Recently, a few studies have reported the protective effect of SGLT2 inhibitor on monocrotaline-induced PAH. However, the effects of canagliflozin on hypobaric hypoxia-induced PAH as well as its mechanism still unclear. In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In addition, canagliflozin inhibited the proliferation and migration of pulmonary arterial smooth muscle cells through suppressing glycolysis and reactivating AMP-activated protein kinase signaling pathway under hypoxia condition. In summary, our findings suggest that canagliflozin is sufficient to inhibit pulmonary arterial remodeling which is a potential therapeutic strategy for PAH treatment

    DeceFL: a principled fully decentralized federated learning framework

    No full text
    Traditional machine learning relies on a centralized data pipeline for model training in various applications; however, data are inherently fragmented. Such a decentralized nature of databases presents the serious challenge for collaboration: sending all decentralized datasets to a central server raises serious privacy concerns. Although there has been a joint effort in tackling such a critical issue by proposing privacy-preserving machine learning frameworks, such as federated learning, most state-of-the-art frameworks are built still in a centralized way, in which a central client is needed for collecting and distributing model information (instead of data itself) from every other client, leading to high communication burden and high vulnerability when there exists a failure at or an attack on the central client. Here we propose a principled decentralized federated learning algorithm (DeceFL), which does not require a central client and relies only on local information transmission between clients and their neighbors, representing a fully decentralized learning framework. It has been further proven that every client reaches the global minimum with zero performance gap and achieves the same convergence rate O(1/T) (where T is the number of iterations in gradient descent) as centralized federated learning when the loss function is smooth and strongly convex. Finally, the proposed algorithm has been applied to a number of applications to illustrate its effectiveness for both convex and nonconvex loss functions, time-invariant and time-varying topologies, as well as IID and Non-IID of datasets, demonstrating its applicability to a wide range of real-world medical and industrial applications

    Development and Validation of a Prognostic Risk Score System for COVID-19 Inpatients: A Multi-Center Retrospective Study in China.

    Get PDF
    Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic. Hospitalized patients of COVID-19 suffer from a high mortality rate, motivating the development of convenient and practical methods that allow clinicians to promptly identify high-risk patients. Here, we have developed a risk score using clinical data from 1479 inpatients admitted to Tongji Hospital, Wuhan, China (development cohort) and externally validated with data from two other centers: 141 inpatients from Jinyintan Hospital, Wuhan, China (validation cohort 1) and 432 inpatients from The Third People's Hospital of Shenzhen, Shenzhen, China (validation cohort 2). The risk score is based on three biomarkers that are readily available in routine blood samples and can easily be translated into a probability of death. The risk score can predict the mortality of individual patients more than 12 d in advance with more than 90% accuracy across all cohorts. Moreover, the Kaplan-Meier score shows that patients can be clearly differentiated upon admission as low, intermediate, or high risk, with an area under the curve (AUC) score of 0.9551. In summary, a simple risk score has been validated to predict death in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); it has also been validated in independent cohorts
    corecore